Herpes Zoster Market Research Report: by Diagnosis (laboratory testing, and others), Treatment and Prevention (Antiviral, Narcotic, Anti-Inflammatory, Antihistamines, Vaccines), Route of Administration (oral, others), by End user – Global Forecast Till 2023
Overview:
Global Herpes Zoster Treatment Market is expected to grow significantly over the forecast period. It is projected to grow at a CAGR of 12.7% over the forecast period. Herpes zoster, also known as shingles, is a viral disease that is caused by the reactivation of varicella-zoster virus. The disease can be triggered by chicken pox. The global herpes zoster market is eyeing for an impressive rise during the forecast period (2018-2023). Market Research Future (MRFR), in their recently published article, revealed that one of the major factors to trigger the growth of this market is the impressive influence of government initiatives and expenditures in the research and development sector.
The herpes zoster market is expected to get led by the US as the country has several patients who are suffering from the disease. In geriatric population, the chance of contracting disease is quite high and the mortality rate in the region is growing with the introduction of advanced medicines. This can be taken as an important thrust-provider. Advanced medicines are also going to have substantial impact on the global herpes zoster market.
Segmental Analysis:
The global herpes zoster market, as per the MRFR study, is segmented into diagnosis, treatment & prevention, route of administration, and end-users.
Based on the diagnosis, the herpes zoster market can be segmented into laboratory testing and others. The laboratory testing segment includes real-time Polymerase Chain Reaction (PCR), immunofluorescent microscopy, and serological testing.
Based on the treatment and prevention segment, the herpes zoster market can be segmented into narcotic medications, antiviral medications, antihistamines, anti-inflammatory medications, capsaicin, anticonvulsants, gels, numbing creams, or patches, vaccines, and others.
Based on the route of administration segment, the herpes zoster market comprises oral, topical, and others.
Based on the end-user segment, the herpes zoster market consists hospitals & clinics, diagnostic centers, home care settings, research & academic institutes, and others. The hospitals & clinics segment is gaining substantial head-start as they are the primary caregiver.
For More Details Browse Complete Report @ http:// https://www.marketresearchfuture.com/reports/herpes-zoster-market-7137
Regional Analysis:
The Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA) are four regions that have been included by MRFR in the study of global herpes zoster market.
The market in the Americas is quite big and it is growing with the support from governments of this region. The region also provides highly advanced healthcare facilities and spreads awareness regarding the infection.
The European region ranks second in terms of valuation. Emerging innovative vaccines for disease herpes zoster are expected to boost the regional market. The APAC and the MEA regions are expected to show substantial growth as effects of the disease is rising. The APAC market is going to benefit from the evolving healthcare infrastructures in emerging economies. In the coming years, the MEA market has the potential to emerge as the fastest growing region. However, the African region may hold back the growth as poor countries from the region are lacking proper healthcare infrastructure and expertise.
Competitive Landscape:
Companies are intensely competitive when it comes to take charge of the global herpes zoster market. MRFR included several of them in their report on the market to profile them and understand latest trends. These companies are Foamix Pharmaceuticals (Israel), Astellas Pharma Inc. (Japan), GlaxoSmithKline plc (UK), Geneone Life Science (South Korea), NAL Pharma (Hong Kong), Merck & Co. Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), TSRL, Inc. (US) and others.
In June 2019, an article published in 2minute medicine revealed that kids who were given varicella vaccine are less likely to show signs of herpes zoster. The research was conducted on people under 18 years of age. The varicella zoster vaccine is a live attenuated vaccine that can be linked with reactivation of the latent herpes zoster.
In a different study, conducted in May 2019, it is revealed that Sky Zoster NBP608 herpes zoster vaccine is at per with Merck’s Zostavax. This could solve South Korea’ problem regarding the launch of Shingrix.
Overview:
Global Herpes Zoster Treatment Market is expected to grow significantly over the forecast period. It is projected to grow at a CAGR of 12.7% over the forecast period. Herpes zoster, also known as shingles, is a viral disease that is caused by the reactivation of varicella-zoster virus. The disease can be triggered by chicken pox. The global herpes zoster market is eyeing for an impressive rise during the forecast period (2018-2023). Market Research Future (MRFR), in their recently published article, revealed that one of the major factors to trigger the growth of this market is the impressive influence of government initiatives and expenditures in the research and development sector.
The herpes zoster market is expected to get led by the US as the country has several patients who are suffering from the disease. In geriatric population, the chance of contracting disease is quite high and the mortality rate in the region is growing with the introduction of advanced medicines. This can be taken as an important thrust-provider. Advanced medicines are also going to have substantial impact on the global herpes zoster market.
Segmental Analysis:
The global herpes zoster market, as per the MRFR study, is segmented into diagnosis, treatment & prevention, route of administration, and end-users.
Based on the diagnosis, the herpes zoster market can be segmented into laboratory testing and others. The laboratory testing segment includes real-time Polymerase Chain Reaction (PCR), immunofluorescent microscopy, and serological testing.
Based on the treatment and prevention segment, the herpes zoster market can be segmented into narcotic medications, antiviral medications, antihistamines, anti-inflammatory medications, capsaicin, anticonvulsants, gels, numbing creams, or patches, vaccines, and others.
Based on the route of administration segment, the herpes zoster market comprises oral, topical, and others.
Based on the end-user segment, the herpes zoster market consists hospitals & clinics, diagnostic centers, home care settings, research & academic institutes, and others. The hospitals & clinics segment is gaining substantial head-start as they are the primary caregiver.
For More Details Browse Complete Report @ http:// https://www.marketresearchfuture.com/reports/herpes-zoster-market-7137
Regional Analysis:
The Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA) are four regions that have been included by MRFR in the study of global herpes zoster market.
The market in the Americas is quite big and it is growing with the support from governments of this region. The region also provides highly advanced healthcare facilities and spreads awareness regarding the infection.
The European region ranks second in terms of valuation. Emerging innovative vaccines for disease herpes zoster are expected to boost the regional market. The APAC and the MEA regions are expected to show substantial growth as effects of the disease is rising. The APAC market is going to benefit from the evolving healthcare infrastructures in emerging economies. In the coming years, the MEA market has the potential to emerge as the fastest growing region. However, the African region may hold back the growth as poor countries from the region are lacking proper healthcare infrastructure and expertise.
Competitive Landscape:
Companies are intensely competitive when it comes to take charge of the global herpes zoster market. MRFR included several of them in their report on the market to profile them and understand latest trends. These companies are Foamix Pharmaceuticals (Israel), Astellas Pharma Inc. (Japan), GlaxoSmithKline plc (UK), Geneone Life Science (South Korea), NAL Pharma (Hong Kong), Merck & Co. Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), TSRL, Inc. (US) and others.
In June 2019, an article published in 2minute medicine revealed that kids who were given varicella vaccine are less likely to show signs of herpes zoster. The research was conducted on people under 18 years of age. The varicella zoster vaccine is a live attenuated vaccine that can be linked with reactivation of the latent herpes zoster.
In a different study, conducted in May 2019, it is revealed that Sky Zoster NBP608 herpes zoster vaccine is at per with Merck’s Zostavax. This could solve South Korea’ problem regarding the launch of Shingrix.
NOTE: Our Team of Researchers are Studying Covid19 and its Impact on Various Industry Verticals and Wherever Required We Will be Considering Covid-19 Footprints for a Better Analysis of Markets and Industries. Cordially Get in Touch for More Details.
No comments:
Post a Comment